Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
August 05, 2022 at 04:15 am EDT
Share
Henan Lingrui Pharmaceutical Co., Ltd. reported earnings results for the half year ended June 30, 2022. For the half year, the company reported sales was CNY 1,502.68 million compared to CNY 1,355.49 million a year ago. Net income was CNY 270.52 million compared to CNY 219.66 million a year ago. Basic earnings per share from continuing operations was CNY 0.49 compared to CNY 0.39 a year ago. Diluted earnings per share from continuing operations was CNY 0.471 compared to CNY 0.39 a year ago.
Henan Lingrui Pharmaceutical Co., Ltd is a China-based company, principally engaged in the research and development, production and distribution of medicines. The Company's products include emplastrum, tablets, capsules, ointments and others, applied in the treatment of diabetes mellitus, osteoarthritis, gastropathy, cardiovascular and cerebrovascular diseases, respiratory disease, gynecopathy and dermatopathy, among others. The Company distributes its products throughout China, with Henan Province and Beijing as its major markets.